New for 2025
Introducing the Regulatory CMC Seminar Day Stream
As ADCs globally advance quickly towards regulatory submissions, understanding necessary specifications, dossier filing data, and evolving regulatory attitudes are vital for successful approval and commercialisation. This redesigned seminar day is perfect for regulatory CMC, MSAT, supply, and process development specialists to tackle ADC modality-specific challenges, streamline impurity control strategy, and discuss the important areas for ongoing industry-regulator communication
Brand-New Presenting ADC Biopharma
Gain fresh insights from new presenting biotechs ABL Bio, Angiex, Avidity Biosciences, and Huadong Medicine; speaking alongside emerging ADC pharma BioNTech, Johnson & Johnson, Ipsen, and Pfizer. Key topics to be discussed include degrader antibody conjugates, bispecific ADCs, translational investigation of novel ADC targets, bioconjugate applications beyond oncology, and navigating ADC acquisition and licensing deals.
Revamped ADC Licensing, Partnering & Investment Session*
This session is exclusively designed for senior search and evaluation, early innovation, and business development leads, C-level biotech leaders, and VC biopharma investors.
Across multi-billion-dollar acquisitions, asset commercialisation deals, and licensing agreements, ADCs are dominating biopharma dealmaking right now as the leaders of the global pharmaceutical world look for a piece of the ADC pie.
Attendees will hear from key companies such as BioNTech, Ipsen, Johnson & Johnson, Multitude Therapeutics, Oxford BioTherapeutics, and Zymeworks before informal networking to foster new relationships for ADC collaboration, partnerships and investment ahead of the main conference days.